Michael Linn
Impact in
- Pharmaceutical Science top 2%
- Drug Solubulity and Delivery Systems
- Advanced Drug Delivery Systems
- Oncology top 10%
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
Papers in
- Oncology 5
- HER2/EGFR in Cancer Research 2
- Cancer Treatment and Pharmacology 1
-
- Angiogenesis and VEGF in Cancer 1
- Co-authors
- Eva-Maria Collnot (1 shared paper)Dejan Djurić (1 shared paper)Claus‐Michael Lehr (1 shared paper)Katja Hempel (1 shared paper)Eric Fabian (1 shared paper)Karl Kolter (1 shared paper)Kenneth Kolinsky (6 shared papers)Brian Higgins (5 shared papers)
- Journals
- Cancer Chemotherapy and Pharmacology (2 papers)Phytotherapy Research (1 paper)Molecular Cancer Therapeutics (1 paper)Clinical Cancer Research (1 paper)Addiction Biology (1 paper)
- Partner nations
- United StatesSwitzerlandSerbia
In The Last Decade
Michael Linn
14 papers receiving 740 citations
Peers
Comparison fields: 5 of 94
- Pharmaceutical Science 156
- Oncology 206
- Molecular Biology 298
- Pulmonary and Respiratory Medicine 103
- Cancer Research 46
Countries citing papers authored by Michael Linn
This map shows the geographic impact of Michael Linn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Linn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Linn more than expected).
Fields of papers citing papers by Michael Linn
This network shows the impact of papers produced by Michael Linn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Linn. The network helps show where Michael Linn may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Linn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 216 | |
| 2 | 2009 | 166 | |
| 3 | 2004 | 129 | |
| 4 | 2014 | 51 | |
| 5 | 2009 | 48 | |
| 6 | 2006 | 42 | |
| 7 | Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model. | 2007 | 23 |
| 8 | 2006 | 21 | |
| 9 | 2010 | 14 | |
| 10 | 2011 | 11 | |
| 11 | 2013 | 11 | |
| 12 | 2013 | 10 | |
| 13 | 2006 | 8 | |
| 14 | 2013 | 3 |
About Michael Linn
Michael Linn is a scholar working on Oncology, Molecular Biology, Cellular and Molecular Neuroscience, Pulmonary and Respiratory Medicine and Pharmacology, having authored 14 papers that have together received 753 indexed citations. Recurring topics across this work include Neuroscience and Neuropharmacology Research (2 papers), Neurotransmitter Receptor Influence on Behavior (2 papers), Lung Cancer Treatments and Mutations (2 papers), HER2/EGFR in Cancer Research (2 papers), Angiogenesis and VEGF in Cancer (1 paper), MRI in cancer diagnosis (1 paper), Neuroendocrine regulation and behavior (1 paper) and Cancer Treatment and Pharmacology (1 paper). The work is most often cited by research in Pharmaceutical Science (156 citations), Oncology (206 citations), Molecular Biology (298 citations), Pulmonary and Respiratory Medicine (103 citations) and Cancer Research (46 citations). Michael Linn has collaborated with scholars based in United States, Switzerland and Serbia. Frequent co-authors include Eva-Maria Collnot, Dejan Djurić, Claus‐Michael Lehr, Katja Hempel, Eric Fabian, Karl Kolter, Kenneth Kolinsky, Brian Higgins, Kathryn Packman and David Heimbrook. Their work appears in journals such as Cancer Chemotherapy and Pharmacology, Phytotherapy Research, Molecular Cancer Therapeutics, Clinical Cancer Research and Addiction Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.